Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
favipiravir + hydroxychloroquine
- Development stage
- Phase 4
- Lead developer
- FUJIFILM Toyama Chemical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of favipiravir and hydroxychloroquine that was investigated for the treatment of COVID-19. Favipiravir is a purine nucleoside analog that selectively inhibits RNA-dependent RNA polymerase (RdRp), preventing viral genome replication. Hydroxychloroquine works by increasing endosomal pH, preventing ACE2 receptor glycosylation, blocking sialic acid receptors, and exerting immunomodulatory effects that reduce cytokine production. Clinical studies showed this combination had efficacy in reducing viral load and hospitalization rates in COVID-19 patients, though with varying side effect profiles.
02
Targets
ACE2 (Angiotensin-converting enzyme 2)RdRp (Coronavirus RNA-dependent RNA polymerase)Sialoglycan (Cell-surface sialoglycan)SA (Sialic acid)
Beyond the preview
Go deeper on favipiravir + hydroxychloroquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on favipiravir + hydroxychloroquine.